SARCULATOR
5K+
Downloads
Everyone
info
About this app
This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician.
Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
No data collected
Learn more about how developers declare collection
What's new
Update: new model for patients with primary RPS taking into consideration the improved outcome over time and the case-volume effect.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.